NeuroVive Pharmaceutical AB is involved in the research and development of mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. The company’s product portfolio includes its drug candidate CicloMulsion, which is in phase 3 clinical study for cell protection against reperfusion injury during heart attack treatment; NeuroSTAT, a drug candidate that is in phase 2a clinical study for the treatment of traumatic brain injuries; and NVP019, an intravenous formulation that is in pre-clinical phase for treating myocardial infarct and traumatic brain injury. For more information, visit the company’s website at www.neurovive.com